Brazilian Pharma Giant EMS Visits Buck Institute

Discussions Focus on Potential Alzheimer’s Collaboration

March 20, 2012  Novato, CA Officials from EMS, the leading pharmaceutical company in Brazil, visited the Buck Institute today to continue discussions aimed at a collaborative agreement to develop therapeutics for Alzheimer’s disease.  EMS Chair Carlos Sanchez and Buck Institute CEO Brian K. Kennedy, PhD, led the talks, which began in São Paulo earlier this year.

EMS is the leading pharmaceutical company in Brazil. Established more than 40 years ago with 100% national capital, the company has two industrial plants strategically placed in São Bernardo do Campo and Hortolândia, in the state of São Paulo. EMS was the first Brazilian laboratory to export medical products to Europe.

“I am pleased with the progress both of our organizations are making toward reaching an agreement that would further research now underway in the laboratory of Buck faculty Dale Bredesen, MD,” said Kennedy. “Given the desperate need for therapeutics for Alzheimer’s disease world-wide, I am confident that we will reach an understanding that will be beneficial to all parties involved."

EMS allocates 6% of company revenues annually to research and development,  as it maintains  an accelerated rhythm of product launches.

About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first and foremost independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, CA, The Buck is dedicated to extending “Healthspan”, the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, macular degeneration, diabetes and stroke.  In their collaborative research, they are supported by the most recent developments in genomics, proteomics and bioinformatics.  

Change text size: